Olmesartan is not metabolized by CYP, and no CYP interaction potential is observed in vitro nor anticipated.

Angiotensin II receptor antagonist. In medicinal products for oral administration, it is available as the prodrug olmesartanmedoxemil.

Olmesartan medoxomil is used in the treatment of essential hypertension.

The prodrug olmesartan medoxomil is rapidly converted to the pharmacologically active metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the gastrointestinal tract (SPC). Olmesartan is not further metabolized, and is excreted primarily via the bile (up to 90 per cent), and the rest by renal excretion (Yang 2016). Olmesartan had no clinically relevant inhibitory effects on in vitro human CYP 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4 (SPC).

Uneventful use reported in 3 patients with acute porphyria.